UroAlert - GU Oncology Weekly

July 09, 2026

Videos

Peer-to-Peer Clinical Conversations

Expanding Bladder Cancer Trials and Multidisciplinary Membership in the SUO-CTC - Trinity Bivalacqua

Trinity Bivalacqua

Trinity Bivalacqua discusses SUO-CTC updates with Ashish Kamat.

CAN-2409 in Localized Prostate Cancer: Protocol, Outcomes, and Patient Perspective - Mark Garzotto & Tom Hulsey

M Garzotto

Mark Garzotto presents updated CAN-2409 data, with Tom Hulsey providing the patient perspective.

Beyond the Abstracts

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology - Beyond the Abstract

Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort Study - Beyond the Abstract

Conference Coverage

AUA 2026: Real-World Darolutamide Safety and Effectiveness in Patients with Nonmetastatic Castration-Resistant Prostate Cancer with Comorbidities and Concomitant Medications: Post Hoc Analyses at DAROL Interim Analysis 4 (IA4)

AUA 2026: Debate: In 2026, MRI with VIRADS is Mandatory for the Staging and Therapeutic planning for Bladder Cancer

AUA 2026: Perioperative and Oncologic Outcomes of Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and Pembrolizumab: A Multicenter Experience

AUA 2026: Long-Term Follow-Up Results of aMVAC Arm of ECOG-ACRIN EA8141: a Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High-Grade Upper Tract Urothelial Carcinoma

EAU 2026: Case-Based Panel Discussion High-Risk NMIBC Post-BCG Failure: Spare the Bladder? How Do Cystectomy and Bladder Sparing Compare When We Ask Patients?

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

The impact of cachexia and sarcopenia in bladder cancer.

Beyond the bladder: case series of Mycobacterium bovis bacillus Calmette-Guérin infections following intravesical instillation.

Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience - Beyond the Abstract

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary Disease.

Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC.

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner.

The role of microRNAs-23b and 27b in migration, invasion and proliferation of T24 bladder cancer cells.

Predictors of residual tumour and recurrence in high-grade NMIBC: insights from a multicenter re-TURBT cohort.

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC).

Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.

A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels.

Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease Sites.

Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Patients with High Body Mass Index or Diabetes Mellitus - Beyond the Abstract

Penile & Urethral Cancers

Scrotal flap phalloplasty and perineal urethrostomy following total penectomy for stage IIIB penile cancer: a case report.

Venous thromboembolism after penile cancer surgery: a UK PeCaN study.

Renal Cancer

Post-treatment renal function deterioration following radiation therapy: implications for SABR in primary renal cell cancer.

Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinoma.

Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial - Beyond the Abstract

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

A Core Outcome Set for Localized Renal Cell Cancer (L-RCC-COS).

Sarcopenia is associated with poor survival among patients with non-metastatic renal cell carcinoma and venous tumor thrombus.

Investigating the determinants of immunotherapy response in the primary tumour of clear cell renal cell carcinoma (RCC).

Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study.

Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size-dependent survival in pT3N0M0 clear cell renal cell carcinoma.

HER2 Expression and Nuclear Localization in Clear Cell Renal Cell Carcinoma: Implications for Prognosis and Therapeutic Targeting.

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.

Prostate Cancer

Blue Earth Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial Investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in Metastatic Castration-Resistant Prostate Cancer

Same-day Hyaluronic Acid rectal spacer for TRUS-guided HDR Prostate Brachytherapy: Feasibility and dosimetric outcomes.

Impact of prostate mpMRI quality on diagnostic accuracy in prostate cancer: a prospective study.

Clinical and racial predictors of adverse pathology at radical prostatectomy: implications for undertreatment among patients receiving radiation and hormonal therapy.

Telehealth Utilization for Prostate Cancer Management in the Veteran Affairs Healthcare System: A Study from 2016 to 2023.

A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.

CorePlus Integrates AI-Powered Prostate Cancer Risk Stratification Tool into its Digital Pathology Diagnostic Pathway — a First in Puerto Rico

Newly diagnosed high-risk localized prostate cancer after multiple [177Lu]Lu-PSMA radioligand therapy in the context of metastatic parotid carcinoma: a case report.

Germline CDK12 variants in aggressive prostate cancer.

Overall Survival with [177Lu]Lu-PSMA-617 Versus [177Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.

Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined 18F-Flotufolastat PSMA PET and mpMRI.

Comparison of DeepSeek-V3.2 and ChatGPT-5.2 in the outpatient diagnosis and treatment of prostate cancer: a multicenter evaluation of application value and multilingual adaptability.

Screening for prognostic indicators in patients with metastatic castration-resistant prostate cancer after androgen receptor signaling inhibitor treatment for metastatic castration-sensitive prostate cancer.

Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.

Comparison of MRI-guided in-bore and fusion biopsy for small PI-RADS 4 prostate lesions.

Racial Differences in Psychosocial Outcomes Among Prostate Cancer Survivors: Insights From the All of Us Research Program.

Artificial intelligence-enabled MRI surveillance of prostate cancer: integrating PRECISE v2, PI-QUAL, and longitudinal biomarkers-a narrative review.

Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Preparation of electroplated zinc-68 targets for gallium-68 cyclotron production using recovered zinc-68.

Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity.

Cancer detection in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

How to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations.

Association between author specialty and reported outcomes in nonrandomized comparisons of prostatectomy versus radiation.

Prostate cancer: Value of the PI-FAB score and volume-adjusted PSA density in recurrence assessment after HIFU.

Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study.

Redefining robotic image-guidance - tomographic visualization of lesions during prostate cancer surgery via gantry-free robotic SPECT.

STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance.

Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.

Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer - Beyond the Abstract

Upper Tract Tumors

National Patterns and Predictors of Perioperative Intravesical Chemotherapy Use Following Nephroureterectomy for Upper Tract Urothelial Carcinoma.

Testicular Cancer

Testis-sparing surgery for small testicular masses: Functional and oncological outcomes.

Prognostic Factors for Relapse and Mortality Risk in Chilean Patients With Testicular Cancer: A Retrospective Cohort Study.

Human iPSCs derived from cryopreserved testicular somatic cells enable germline regeneration in childhood cancer survivors.

Presentation, Management, and Outcomes of Testicular Germ Cell Tumors by Age - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC